Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/77652
Title: Maternally inherited hypercholesterolemia does not modify the cardiovascular phenotype in familial hypercholesterolemia
Authors: Marco-Benedí, Victoria
Laclaustra, Martín
Bea, Ana M.
Suárez-Tembra, Manuel
Plana, Núria
Pinto, Xavier
Brea, Angel
Sánchez Hernández, Rosa María 
Civeira, Fernando
UNESCO Clasification: 32 Ciencias médicas
320702 Artereoesclerosis
320501 Cardiología
Keywords: Hefh Phenotype
Heterozygous Familial Hypercholesterolemia
Low-Density Lipoprotein Receptor
Mother-Offspring
Issue Date: 2021
Journal: Atherosclerosis 
Abstract: Background and aims: Familial hypercholesterolemia (FH) is a codominant autosomal disease characterized by a high risk of cardiovascular disease when not in lipid-lowering treatment. However, there is a large variability in the clinical presentation in heterozygous subjects (HeFH). Maternal hypercholesterolemia has been proposed as a cardiometabolic risk factor later in life. Whether this phenotype variability depends on the mother or father origin of hypercholesterolemia is unknown. The objective of this study was to analyze potential differences in anthropometry, superficial lipid deposits, comorbidities, and lipid concentrations depending on the parental origin of hypercholesterolemia within a large group of HeFH. Methods: This is a cross-sectional observational, multicenter, nation-wide study in Spain. We recruited adults with HeFH to study clinical differences according to the parental origin. Data on HeFH patients were obtained from the Dyslipidemia Registry of the Spanish Atherosclerosis Society. Results: HeFH patients were grouped in 1231 HeFH-mother-offspring aged 45.7 (16.3) years and 1174 HeFH-father-offspring aged 44.8 (16.7) years. We did not find any difference in lipid parameters (total cholesterol, triglycerides, LDLc, HDLc, and Lp(a)), nor in the comorbidities studied (cardiovascular disease prevalence, age of onset of cardiovascular disease, obesity, diabetes, and hypertension) between groups. Lipid-lowering treatment did not differ between groups. The prevalence of comorbidities did not show differences when they were studied by age groups. Conclusions: Our research with a large group of subjects with HeFH shows that a potential maternal effect is not relevant in FH. However, due to the size of our sample, potential differences between genders cannot be completely ruled out. This implies that severe maternal hypercholesterolemia during pregnancy is not associated with additional risk in the FH affected offspring.
URI: http://hdl.handle.net/10553/77652
ISSN: 0021-9150
DOI: 10.1016/j.atherosclerosis.2021.01.015
Source: Atherosclerosis [ISSN 0021-9150],v. 320, p. 47-52, (Marzo 2021)
Appears in Collections:Artículos
Show full item record

Page view(s)

18
checked on Mar 7, 2021

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.